| Autor: |
Soares, Claudia, Abreu, Gabriela, Nogueira da Silva, Thiago Luiz, Queiroz, Juliana, Menezes, Patricia, Bernardino, Graziela, Pires, Tatiana, Carrizo, Mariano, Felice, Rosana, Riggi, Maria Cecilia, Cravero, Florencia, Ribeiro de Souza, André Luiz Alves, Jotimliansky, Laura |
| Zdroj: |
Future Oncology; 2024, Vol. 20 Issue 27, p2023-2036, 14p |
| Abstrakt: |
Aim: To evaluate real-world data on treatment patterns in Argentina and Brazil in patients with ovarian cancer. Methods: This study evaluated de-identified antineoplastic exposure data from a private healthcare provider in Argentina and health claims database (Orizon) in Brazil from 2010 to 2019 and 2015 to 2020, respectively. Results: Platinum-based chemotherapy was the most common first-line therapy (Argentina: n =311 [87.6%]; Brazil: n = 1142 [79.3%]). The proportion of patients receiving platinum-based chemotherapy declined across both populations from first- to second-line, while use of non–platinum-based, targeted, and hormone therapies increased. Duration of platinum-based treatment and time to next treatment decreased from first- to fourth-line. Conclusion: There is an unmet need for effective therapies that can prolong time to next treatment in ovarian cancer in Argentina and Brazil. Antineoplastic exposure data were captured from databases in Argentina (Hospital Italiano de Buenos Aires) and Brazil (Orizon) from 2010 to 2019 and 2015 to 2020, respectively, and treatment patterns were described across multiple lines of therapy for patients with ovarian cancer (OC). In total, 741 patients from Argentina and 2529 patients from Brazil were identified. Across both countries, around 50% of patients with OC did not receive antineoplastic agents postdiagnosis. Of the 355 patients from Argentina and 1441 patients from Brazil who received 1L therapy, the most commonly received treatment was platinum-based chemotherapy. Use of platinum-based chemotherapy declined from the 1L to the 4L in Argentina (1L: n = 311, 87.6%; 4L: n = 29, 37.7%) and Brazil (1L: n = 1142, 79.3%; 4L: n = 40, 33.3%). Median time to next treatment between a line of any antineoplastic agent and the next line of any antineoplastic agent was longest between the 1L and 2L settings, with a median of 5.3 months (interquartile range [IQR]: 10.7 months) and 3.0 months (IQR: 6.8 months) in Argentina and Brazil, respectively. Median progression-free survival was 6.0 months (IQR: 11.3) in patients from Argentina and 3.6 months (IQR: 9.6) in patients from Brazil. Median duration of treatment was the longest in 1L therapy across both countries (Argentina: 4.4 [IQR: 3.3] months; Brazil: 3.5 [IQR: 3.5] months) and became shorter across successive lines of therapies. These findings highlight the unmet need for effective therapies to optimize outcomes in patients in Argentina and Brazil with ovarian cancer, particularly those with advanced disease. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
